

# **Vulvovaginal candidiasis at Institute Pasteur of Dakar, Senegal: Prevalence and associated risk factors**

## **Abstract**

Vulvovaginal candidiasis (CVV) is a superficial mycosis caused by *Candida* spp. with a predominance of *C. albicans*. CVV is opportunistic with several incriminated risk factors. This study aimed to determine the prevalence of CVV and to investigate potential risk factors. A cross-sectional study was carried out at the Medical Biology Laboratory in Pasteur Institute in Dakar, Senegal from September 1 to November 30, 2020. The study cohort was inclusive of all women received for a vaginal swab test in the laboratory unit. Each patient's socio-demographic and clinical data were recorded before collecting two swabs samples for direct examination and culture on CHROMagar Candida incubated at 37 °C for 24 to 48 h.

A total of 312 women with an average age of 32 years (range: 17-74) were included in this study. An overall CVV prevalence of 32% was found. *C. albicans* was predominant (73.2%) followed by *C. glabrata* (16.8%). The age group [30-40 years] was more infested with 35.3% ( $p = 0.434$ ) as well as nulliparous or primiparous women with 38.7% ( $p = 0.171$ ). CVV was more associated with disordered vaginal flora and pregnancy with 35.2% ( $p = 0.323$ ) and 33.7% ( $p = 0.715$ ) respectively. CVV was significantly related to contraception ( $p = 0.014$ ). An overall high prevalence of CVV was observed mainly due to *C. albicans*. Contraception seems to be a factor contributing to its occurrence.

**Keywords:** candidiasis, species, risk factors.

## **Introduction**

Vulvovaginal candidiasis (VVC) is a cosmopolitan, opportunistic superficial mycosis caused by commensal yeast belonging to the genus *Candida* [1]. The transition from colonization to the onset of symptomatic infection is associated with multiple factors including host susceptibility, host inflammatory reactions, and virulence factors of the *Candida* species involved. The species responsible are varied with a predominance of *C. albicans* and *C. glabrata* [2].

Clinical symptoms of VVC are thought to be caused by an overabundance of yeast and its penetration into the vulvovaginal epithelial cells [3]. This clinic is characterized by vulvar pruritus and whitish, curdled leucorrhoea which will cause significant discomfort for the patients [4,5].

VVC is also known for its high direct or indirect economic cost associated with its management [5]. Indeed, CVV is often recurrent (RVVC) characterized by four or more episodes per year [3].

Several risk factors have been implicated in the occurrence of CVV, including sexual activity, recent use of antibiotics, pregnancy, and immunosuppression due to situations such as poor control of HIV infection or diabetes [6,7].

Regarding the frequency of VVC with around 75% of women contracting it at least once in their lifetime, i.e. 138 million per year worldwide [8], we volunteered to participate in the documentation of VVC in Senegal. More specifically, it involved determining the prevalence of VVC, to identify the species involved and to specify potential associated risk factors.

## **Materials and methods**

This is a cross-sectional and descriptive study carried out in the Medical Biology Laboratory of the Pasteur Institute in Dakar (Senegal) from September 1 to November 30, 2020.

The study population included women received in the laboratory for microbiological analysis of vaginal swab (VS) and who met the required conditions. Sociodemographic and clinical data (age, type of flora, parity, contraception) was recorded for each patient included before sample collection.

VS were sampled by collecting vaginal discharges or secretions mainly found in the posterior fornices after placement of a speculum unless contraindicated. Two swabs were used, one for direct examination and the other for culture. For direct examination, we performed a microscopic examination after Gram stain for flora typing with Nugent scores [9]. The culture was realized by inoculating the samples on CHROMagar Candida (Becton Dickinson, USA)

chromogenic medium which was then incubated at 37 °C. The cultures were read after 24 and 48 hours.

The mycological diagnosis of VVC was retained by a positive direct examination associated with a positive culture showing the presence of 10 yeast colonies at least. The presumptive identification of *Candida* species was performed according to the manufacturer's instructions according to the following color code: light to medium green (*C. albicans*), light rose to pink with a whitish border (*C. glabrata*), blue greenish to metallic blue with or without violet halos (*C. tropicalis*), fuchsia pink (*C. krusei*), yellow (*C. parapsilosis*).


For statistical analysis, collected data were entered into MS Excel 2010 and then transferred to the SPSS 20.0 software with which they were analyzed. Pearson's chi-square test was used to compare the differences and significance was considered if  $p < 0.05$ .

## Results

In sum, 312 women were included in the study with a mean age of 32 years ranging from 17 to 74 years. The most represented age group was between 30 and 40 years old with 136 women (43.6%). Women with normal vaginal flora accounted for 53.8% (n = 168) and 56.4% (n = 174) of women were primiparous or nulliparous. Pregnant women represented 23.7% (n = 74) and those using contraception 9.9% (n = 31).

Out of these 312 women included, VVC was diagnosed in 100 corresponding to an overall prevalence of 32%.

The distribution of VVC according to the species involved showed a large predominance of *C. albicans* followed by *C. glabrata* with 73% and 16% respectively. Two patients presented co-infection with *C. albicans* associated with *C. glabrata* or *C. krusei* (**Figure 1**).



**Figure 1:** Distribution of *Candida* infection by species

The VVC infestation index was found more in the age group between 20 and 40 years with 73% ( $p = 0.261$ ) and in nulliparous and/or primiparous women with 35.2% ( $p = 0.171$ ). The infection was more associated with a disordered flora with a frequency of 38.3% ( $p = 0.323$ ). VVC was found in more pregnant women with a frequency of 33.8% ( $p = 0.715$ ). No correlation between VVC and the following factors was found: age, parity, type of vaginal flora, and pregnancy (**Table 1**). However, VVC was significantly related to contraception with a frequency of 51.6% ( $p = 0.014$ ).

**Table 1:** Sociodemographic and clinical characteristics of the patients (n = 312)

Characteristics	Examined	Positives	<i>p-value</i>
	n (%)	n (%)	
<b>Age group (years)</b>			
<20	2 (0,6)	1 (1)	0,261
20 - 40	210 (67,3)	73 (73)	
≥ 40	100 (32,1)	26 (26)	
<b>Parity</b>			
≤ 1	84 (54,9)	62(35,2)	0,171
≥ 2	15 (9,8)	38 (27,9)	
<b>Type of flora(Nugent score)</b>			
Normal(	168 (53,8)	48(28,6)	0,323
Intermediate	84 (26,9)	29(34,5)	
Imbalanced (vaginosis)	60 (19,2)	23(38,3)	
<b>Pregnancy</b>			
Yes	74 (27,3)	25(33,8)	0,715
No	238 (76,7)	75(31,5)	
<b>Contraception</b>			
Yes	31 (9,9)	16(51,6)	0,014
No	281 (90,1)	84(29,9)	

## Discussion

VVC is one of the most frequent infections of the vulvovaginal tract in women [10], representing a very serious pathology with a considerable economic burden related to its management.

In our study, the prevalence of VVC was estimated at 32%.

Prevalence of VVC was previously estimated in Senegal at 24% in 2006 during a national survey, at 34.8% in 2008 in Aristide Le Dantec university hospital and at 27.2% in 2015 in Ouakam military hospital in Dakar region respectively according to citation of Diongue et al, (2018) [1].

Globally, the prevalence of this infection is variable [5]. In Africa, a prevalence of 22.8% was reported in Morocco in 2009 [11], 38.9% in Benin in 2014 [5], 41.3 in Ivory Cost in 2011 [12], and 26% in Mauritania [10]. In Europe, high prevalence has also been reported, particularly in Sweden (42.0%) and Italy (43.5%) [13,14]. Similar results were reported in Turkey with a prevalence of 40.0% [15].

Our results showed that *C. albicans* was the most isolated species (73.2%) followed by *C. glabrata* (16.8%).

This same trend has been reported by almost all authors, particularly in Gabon where *C. albicans* and *C. glabrata* were isolated at 70.2% and 9.6% respectively [16] as well as in Benin where *C. albicans* was isolated at 96.1% followed by *C. glabrata* with 3.9% [5]. In several other studies, proportions ranging from 60 to 90% for *C. albicans* were reported especially in Brazil and in Tunisia [2,17].

The predominance of *C. albicans* could be explained by its ability to adhere to the vaginal mucosa by the expression of virulence factors including germ tub formation and switch from the saprophytic state (yeast form) to the pathogenic state (filamentous form). [5,18]. Thus, *C. albicans* which is a commensal yeast of the genital and gastrointestinal tract, is responsible for 85 to 90% of VVCs. However, in recent years, there has been an emergence of "non albicans" *Candida* species, essentially *C. glabrata* isolated with a prevalence of 5 to 15% of VVC cases while *C. parapsilosis*, *C. tropicalis*, and *C. krusei* are less rarely isolated [17,19].

"non-albicans" species (15 to 47%) have been particularly involved in the pathogenesis of RVVC with a predominance of *C. glabrata* ranging from 6 to 29% [17].

The emergence of "non-albicans" species could be explained by selective pressure due to prolonged antifungals drugs exposure in women suffering from RVVC [20].

Several risk factors are associated with the occurrence of VVC. During this study, we observed that VVC was more associated with disordered vaginal flora such as vaginosis.

Such an observation has already been found in Benin [5]. This could be explained by the fact that *Candida* spp. behaves as opportunists in this favorable environment for the development of microorganisms habitually considered as commensals. Indeed, once again *C. albicans* is an opportunistic yeast of the vaginal mucosa which can switch from commensal

form to pathogenic form according to a disorder of the stability between the local host immune system and the virulence mechanisms of the fungus. This disorder induces the expression of virulence factors by the yeast and the colonization of the vaginal mucosa [17].

Regarding age, VVC has been observed more in women aged between 20 and 40 years who can be considered a sexually active group.

This result is phase with those several other authors [5,21,22]. Certain very common practices among women in this age group such as using particular clothing or undergarments (made of synthetic fabric and tight clothing), intimate hygiene (frequent use of antiseptic products) as well as the frequency of sexual practices, especially intercourse or oro-genital, are emerging as potential factors in VVC [13].

The increase in hormonal activity, especially estrogenic which is associated with highest sexual activity at this age would explain why that age is a risk factor as reported by several authors [18,23]. The frequency of VVC tends to decrease as we observed in our study.

We also noticed that VVC was more associated with pregnancy although we did not find a statistically significant difference, the same has been reported in several other studies [5,10,17]. Indeed, this could be the result of a strong hormonal change; pregnancy corresponds to a period of greatest risk. The hormonal disorder observed during this period (predominant role of progesterone) causes a modification of the vaginal epithelium and a drop in vaginal pH, allowing the implantation of yeasts of the genus *Candida*. Furthermore, this high concentration of progesterone is also responsible for increasing the glycogen content in the vaginal tissue which provides a source of carbon for *Candida*, thus promoting their multiplication [5].

Likewise, CVV was significant more found among women under contraception. Indeed, contraception is a situation quite similar to pregnancy with a hormonal disorder thus promoting the proliferation of *Candida* spp. Mechanical contraceptives (intrauterine device-IUD, vaginal ring) contribute to the pathogenesis of VVC/RVVC. Recent studies show that *C. albicans* have a high capacity for adhesion and production of biofilm on the surface of the IUD, allowing them to escape host immunity and reduce their sensitivity to antifungals [17,24].

Contrastingly, we did not find any correlation between CVV and multiparity. This agrees with the results of other studies carried out in particular in Morocco and in Benin [5,11].

## **Conclusion**

Our study showed that CVV is a common condition, especially found in women aged between 20 and 40 years, as well as in an vaginal flora disorder, in pregnant women or under contraception. Despite the high frequency of CVV in its clinical situations, we have only found a correlation of CVV with contraception. Identifying the species involved and the contributing factors could be an important element in better understanding the epidemiology and pathophysiology of this infection.

### **Ethical Approval:**

As per international standard or university standard written ethical approval has been collected and preserved by the author(s).

### **Acknowledgement**

We would like to thank all the colleagues in the medical biology laboratory for their unwavering investment in carrying out this work, particularly in the bacteriology unit. We would also like to thank all of the study participants.

Special mention to employees of the Parasitology-Mycolology and Bacteriology-Virology departments of the Aristide Le Dantec Hospital.

### **References**

[1]. Diongue K, Baha Z, Seck MC, Ndiaye M, Diallo MA, Ndiaye D. Candidoses cutané-unguérales diagnostiquées au laboratoire de parasitologie et mycologie du CHU Le Dantec de Dakar de 2008 à 2015. *Med Sante Trop.* 2018 ; 390-4.

[2]. Mascarenhas REM, Machado MSC, Costa e Silva BFB da, Pimentel RFW, Ferreira TT, Leoni FMS, et al. Prevalence and risk factors for bacterial vaginosis and other vulvovaginitis in a population of sexually active adolescents from Salvador, Bahia, Brazil. *Infect Dis Obstet Gynecol.* 2012 ; 2012 : 378640.

[3]. van Schalkwyk J, Yudin MH, Yudin MH, Allen V, Bouchard C, Boucher M, et al. Vulvovaginite : Dépistage et prise en charge de la trichomonase, de la candidose vulvovaginale et de la vaginose bactérienne. *Journal of Obstetrics and Gynaecology Canada.* 1 mars 2015 ; 37(3) : 275-6.

[4]. Ringdahl EN. Treatment of recurrent vulvovaginal candidiasis. *Am Fam Physician*. 1 Juin 2000;61(11):3306-12, 3317.

[5]. Ogouyèmi-Hounto A, Adisso S, Djamal J, Sanni R, Amangbegnon R, Biokou-Bankole B, et al. Place des candidoses vulvo-vaginales au cours des infections génitales basses et facteurs de risque associés chez les femmes au Bénin. *Journal de Mycologie Médicale*. 1 juin 2014;24(2):100-5.

[6].de Leon EM, Jacober SJ, Sobel JD, Foxman B. Prevalence and risk factors for vaginal *Candida* colonization in women with type 1 and type 2 diabetes. *BMC Infect Dis*. 2002;2:1.

[7].Ohmit SE, Sobel JD, Schuman P, Duerr A, Mayer K, Rompalo A, et al. Longitudinal study of mucosal *Candida* species colonization and candidiasis among human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. *J Infect Dis*. 1 Jul 2003;188(1):118-27.

[8].Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis: a systematic review. *Lancet Infect Dis*. nov 2018;18(11):e339-47.

[9].Delaney ML, Onderdonk AB. Nugent score related to vaginal culture in pregnant women<sup>11</sup>The Microbiology and Prematurity Study Group consists of the following: Robin Ross, Ph.D., Mei-Ling Lee, Ph.D., Andrea M. DuBois, BS, Wendy Osterling, BS, and David G. Aiello, BS, Channing Laboratory, Brigham and Women's Hospital, Boston, MA; and Ruth Tuomala, MD, Ellice Lieberman, MD, Amy Cohen, BA, Dorothy Pender, RN, and Linda Steele, MT(ASCP), Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA. *Obstetrics & Gynecology*. 1 Jul 2001;98(1):79-84.

[10].Sy O, Diongue K, Ahmed CB, Ba O, Moulay FC, Lo B, et al. Candidoses vulvo-vaginales chez les femmes enceintes au centre hospitalier Mère et Enfant de Nouakchott (Mauritanie). *Journal de Mycologie Médicale*. 1 juin 2018;28(2):345-8.

[11].Benchellal M, Guelzim K, Lemkhente Z, Jamili H, Dehainy M, Rahali Moussaoui D, et al. La candidose vulvo-vaginale à l'hôpital militaire d'instruction Mohammed V (Maroc). Journal de Mycologie Médicale. 1 juin 2011;21(2):106-12.

[12].Masson E. Sensibilité *in vitro* des souches de *Candida albicans* d'origine vaginale aux antifongiques à Abidjan (Côte d'Ivoire) [Internet]. EM-Consulte. [cité 26 déc 2020]. Disponible sur: <https://www.em-consulte.com/article/728149/sensibilite-in-vitro-des-souches-de-candida-albicans>

[13].Rylander E, Berglund A, Krassny C, Petrini B. Vulvovaginal candida in a young sexually active population: prevalence and association with oro-genital sex and frequent pain at intercourse. Sex Transm Infect. févr 2004;80(1):54-7.

[14].Corsello S, Spinillo A, Osnengo G, Penna C, Guaschino S, Beltrame A, et al. An epidemiological survey of vulvovaginal candidiasis in Italy. Eur J Obstet Gynecol Reprod Biol. 10 sept 2003;110(1):66-72.

[15].Ilkit M, Guzel AB. The epidemiology, pathogenesis, and diagnosis of vulvovaginal candidosis: a mycological perspective. Crit Rev Microbiol. août 2011; 37(3): 250-61.

[16].Nzenze-Afene S, Mabika-Mamfoumbi M, Mourou-Mbina JR, Fotso A. Candidoses vulvovaginales a Libreville : aspects cliniques, mycologiques et première identification de *Candida africana*. Journal de Mycologie Médicale. 1 juin 2014 ; 24(2) : e87.

[17].Amouri I, Abbes S, Sellami H, Makni F, Sellami A, Ayadi A. La candidose vulvovaginale : revue. Journal de Mycologie Médicale. 1 juin 2010;20(2):108-15.

[18]. Sobel JD. Vulvovaginal candidosis. Lancet. 9 juin 2007;369(9577):1961-71.

[19]. Sobel JD. Vulvovaginitis due to *Candida glabrata*. An emerging problem. Mycoses. 1998;41 Suppl 2:18-22.

[20]. Reid G, Dols J, Miller W. Targeting the vaginal microbiota with probiotics as a means to counteract infections. *Curr Opin Clin Nutr Metab Care*. nov 2009;12(6):583-7.

[21]. An epidemiological study of vulvovaginal candidiasis in women of childbearing age  
Jindal N, Gill P, Aggarwal A - *Indian J Med Microbiol* [Internet]. [cité 26 déc 2020].  
Webpage: <https://www.ijmm.org/article.asp?issn=0255-0857;year=2007;volume=25;issue=2;spage=175;epage=176;aulast=Jindal>

[22].Tarry W, Fisher M, Shen S, Mawhinney M. *Candida albicans*: the estrogen target for vaginal colonization. *J Surg Res*. déc 2005;129(2):278-82.

[23].Anane S, Kaouech E, Zouari B, Belhadj S, Kallel K, Chaker E. Les candidoses vulvovaginales : facteurs de risque et particularités cliniques et mycologiques. *Journal de Mycologie Médicale*. 1 mars 2010;20(1):36-41.

[24]. Auler ME, Morreira D, Rodrigues FFO, Abr Ao MS, Margarido PFR, Matsumoto FE, et al. Biofilm formation on intrauterine devices in patients with recurrent vulvovaginal candidiasis. *Med Mycol*. févr 2010;48(1):211-6.